NCT04666090View on ClinicalTrials.gov

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

November 30, 2030

Conditions
Esophageal Squamous Cell CarcinomaNeoadjuvant Therapy
Interventions
DRUG

Carillizumab

administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4. Preoperative neoadjuvant therapy for 2-3 cycles, one cycle every 14 days.

PROCEDURE

Esophagectomy

Laparoscopy combined with thoracoscope radical resection of esophageal carcinoma

OTHER

Samples

Blood, Tumour and Saliva will be Collected from participant. Fate of sample is Destruction after use

Trial Locations (1)

310009

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER